Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform: Figure 1.

Abstract

Continued progress in addressing challenges associated with detection and management of tuberculosis requires new diagnostic tools. These tools must be able to provide rapid and accurate information for detecting resistance to guide selection of the treatment regimen for each patient. To achieve this goal, globally representative genotypic, phenotypic, and clinical data are needed in a standardized and curated data platform. A global partnership of academic institutions, public health agencies, and nongovernmental organizations has been established to develop a tuberculosis relational sequencing data platform (ReSeqTB) that seeks to increase understanding of the genetic basis of resistance by correlating molecular data with results from drug susceptibility testing and, optimally, associated patient outcomes. These data will inform development of new diagnostics, facilitate clinical decision making, and improve surveillance for drug resistance. ReSeqTB offers an opportunity for collaboration to achieve improved patient outcomes and to advance efforts to prevent and control this devastating disease.

Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State

“…Publicly released in 2008, the TB Drug Resistance Mutation Database (TBDReaMDB) was one of the earliest centralized databases compiling potential resistance-associated mutations from a systematic literature review, providing a valuable resource for molecular M. tuberculosis diagnostics and further research in this field (38). Since the initial release of TBDReaMDB, efforts to build upon this data set to construct curated databases linking genotype data with phenotypic DST results have been undertaken and are critical to improving the accuracy of molecularbased susceptibility profiling (39)(40)(41).…”

Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria

“…• Finally, an ongoing new development is ReSeqTB (Relational Sequencing TB Data Platform), which seeks to increase the understanding of the genetic basis of resistance by correlating molecular data with results from drug susceptibility testing and, optimally, associated patient outcomes (582). The ReSeqTB consortium is jointly managed by the Critical Pathways to TB Regimens (CPTR), the Foundation for Innovative New Diagnostics (FIND), the WHO, the CDC, the New Diagnostics Working Group (NDWG), and the National Institute of Allergy and Infectious Diseases (NIAID), and investigators are invited to contribute anonymized genotypic, phenotypic, demographic, and/or clinical data from M. tuberculosis studies that reside in their respective repositories to the ReSeqTB database.…”

Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination

“…This includes rapid diagnostic tests and more conventional approaches such as microscopy, culture, drug susceptibility testing and sequencing. 13 Inter-connecting these diagnostic devices and further integrating this information with clinical indicators is the upcoming challenge for the TB community.…”